Agilent Technologies, Inc.

Agilent Technologies, Inc.

Agilent Technologies, Inc.

Overview
Date Founded

1999

Headquarters

5301 Stevens Creek Boulevard,Santa Clara, CA 95051

Type of Company

Public

Employees (Worldwide)

14.8K

Industries

Industrial Machinery & Manufacturing
Wholesale: Industrial Products & Manufacturing
IT Consulting & Services
Appliances & Electronics
Semiconductors
Medical Support Services
Electrical Products
Computer Software
Biotechnology

Company Description

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Contact Data
Trying to get in touch with decision makers at Agilent Technologies, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Senior Vice President & Chief Financial Officer

Senior Vice President, General Counsel & Secretary

Senior Vice President & Chief Technology Officer

Vice President, Corporate Controller & Chief Accounting Officer

Chief Infrastructure Officer & Senior Vice President

Senior Vice President-Strategy & Development

Vice President, Assistant General Counsel & Assistant Secretary

President, Life Sciences & Applied Markets Group

President, Agilent Crosslab Group

Board of Directors

Former Executive Chairman & Chief Executive Officer at Sunningdale Tech Ltd.

Co-Founder at Outpost Medicine LLC

President at The University of Texas - Southwestern Medical Center

Former Chief Financial Officer at BevMo Holdings LLC

President & Chief Executive Officer at Varian Medical Systems, Inc.

President & Chief Executive Officer at Lilly ICOS LLC

Director at Exelixis, Inc.

Chief Executive, Air BP & Marine Fuels at BP America Production Co.

Chief Executive Officer at Grail, Inc.

President at SAP SE

Paths to Agilent Technologies, Inc.
Potential Connections via
Relationship Science
You
Agilent Technologies, Inc.
Owners & Shareholders
Details Hidden

Artisan Partners' investment approach is based on a bottom-up process that covers a range of geographic areas and focuses on investments in growth and value stocks. The firm places particular emphasis on identifying and investing in well-managed companies with dominant or increasing market shares. They also closely monitor market valuation. Artisan Partners' autonomous investment teams oversee a range of investment strategies across multiple asset classes including, but not necessarily limited to: global equity, US value, growth, global value, international value, emerging markets, credit, developing world and thematic. All accounts managed by Artisan Partners regardless of investment strategy, invest primarily in common stocks and other equity securities.

Details Hidden

FPP is a value-oriented manager which focuses on absolute, as well as relative performance. Through their funds they generally seek to invest in quality companies that are temporarily out of favor with the market which have the potential of doubling the investment in two to three years with little risk. The firm constructs relatively conservative portfolios comprised of companies able to sustain earnings and cash flow growth in a variety of economic conditions. They try to identify future micro-economic trends and focus on companies benefiting from these trends before they become widely apparent to Wall Street. FPP aims to invest in businesses where it is possible to fully understand the fundamentals. They seek to invest in regions where the economic growth is robust and sustainable or where growth prospects are improving. They have the discipline to sell when everything looks positive and is reflected in the company's valuation. The Findlay Park American Fund aims to achieve capital growth principally through investment in the securities of companies in the Americas. FPP invests the fund in the following sectors: Financials, Information Technology, Health Care, Communication Services, Industrials, Materials, Consumer Staples, Energy, Consumer Discretionary, Real Estate, and Cash & Fixed Interest.

Details Hidden

The D. E. Shaw group pursues attractive and sustainable risk-adjusted returns on the capital we invest for our clients. The firm invests globally using a broad array of strategies in both public and private markets. Widely recognized as a pioneer in quantitative investing, particularly in equities, futures, and options, the firm also has formidable expertise in areas that involve fundamental analysis or portfolio manager discretion, such as credit, energy, and macro investing. Regardless of the particular strategy, each investment decision is made in the context of a rigorous analytical approach that seeks to carefully identify and weigh potential risks and rewards. The firm's investment activities fall into two broad areas: Alternative Investments Strategies focused on the delivery of absolute returns, with low targeted correlation to traditional assets like equities, account for around $21 billion of the firm's investment capital. Our alternative investment program dates to 1989 and consists of both larger, core multi-strategy investment vehicles and more focused, strategy-specific investment products. Benchmark-Relative Investments A suite of long-only and "130/30" equity investment strategies, in either commingled investment vehicles or separately managed accounts, collectively represent approximately $7 billion of the firm's investment capital. These strategies, begun in the year 2000, enable institutional investors to customize their exposure to a particular benchmark index and to choose a targeted level of risk.

Recent Transactions
Details Hidden

Agilent Technologies, Inc. purchases BioTek Instruments, Inc. from Lionheart Technologies, Inc.

Details Hidden

Agilent Technologies, Inc. purchases ACEA Biosciences, Inc. from Qiming Venture Partners Ltd., Lilly Asian Ventures

Details Hidden

Agilent Technologies, Inc. purchases Youngin Scientific Co. Ltd. /Agilent Technology Div from Youngin Scientific Co., Ltd.

Insider Transactions
Details Hidden
Transaction Advisors
Auditor

Advised onAgilent Technologies, Inc. issued USD Common Stock

Legal Advisor

Advised onAgilent Technologies, Inc. purchases Varian, Inc.

Legal Advisor

Advised onAgilent Technologies, Inc. purchases Silicon Genetics, Inc.

Co-Chair, Mergers & Acquisitions

Advised onAgilent Technologies, Inc. purchases Varian, Inc.

Legal Advisor

Advised onAgilent Technologies, Inc. purchases Varian, Inc.

Legal Advisor

Advised onAgilent Technologies, Inc. purchases LaserGen, Inc.

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Senior Advisor

Non-Executive Chair at Southern California Edison Co.

Legal Advisor

Co-Chair, Global Intellectual Property Practice Group at Gibson, Dunn & Crutcher LLP

Clients

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Mellanox Technologies (NASDAQ: MLNX, TASE: MLNX) is a leading supplier of end-to-end InfiniBand and Ethernet interconnect solutions and services for servers and storage. Mellanox interconnect solutions increase data center efficiency by providing the highest throughput and lowest latency, delivering data faster to applications and unlocking system performance capability. Mellanox offers a choice of fast interconnect products: adapters, switches, software and silicon that accelerate application runtime and maximize business results for a wide range of markets including high performance computing, enterprise data centers, Web 2.0, cloud, storage and financial services. More information is available at www.mellanox.com.

Founded in 1979, McGrath RentCorp manages a diversified portfolio of business-to-business equipment rental providers worldwide. Our businesses serve a broad spectrum of industries, including telecommunications, construction, education, petrochemical and environmental. McGrath RentCorp is a California corporation headquartered in Livermore, CA with branch offices located throughout North America, Malaysia, Mexico and India. We are traded on the NASDAQ Global Select Market under the symbol “MGRC.” McGrath RentCorp is a diversified business-to-business rental company with three primary rental divisions: relocatable modular buildings, electronic test equipment and liquid and solid containment tanks and boxes

Key Stats and Financials As of 2018
Market Capitalization
$22.8B
Total Enterprise Value
$20.6B
Earnings Per Share
$0.97
Revenue
$4.91B
Net Profit
$316M
EBITDA
$1.14B
EBITDAMargin
23.22%
Total Debt
$1.8B
Total Equity
$4.57B
Enterprise Value Sales
4.19x
Enterprise Value EBITDAOperating
18.07x
TEVNet Income
65.23x
Debt TEV
0.09x
Three Year Compounded Annual Growth Rate Of Revenue
6.76%
Five Year Compounded Annual Growth Rate Of Revenue
-6.24%
Non-Profit Donations & Grants
Political Donations
$1,000
2008
$1,000
2006
$2,500
2003
Investments
Details Hidden

Gen9, Inc. engages in the development of synthetic biology technologies. It transforms synthetic biology by creating technologies to increase innovation within several industries including biopharmaceuticals, fine chemicals and bio-fuels. The company was founded by Joseph M. Jacobson, George Church and Drew Endy in 2009 and is headquartered in Cambridge, MA.

Details Hidden

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Details Hidden

NanoCellect Biomedical, Inc. develops flow cytometry and cell sorting technology solutions for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine. Its products include wolf cell sorter and N1 single cell dispenser. The company was founded by Nate Heintzman and Yuhwa Lo in 2009 and is headquartered in San Diego, CA.

Investors
Details Hidden

Investor at Zagster, Inc.

Suppliers
Xilinx, Inc. Computer Hardware | SAN JOSE, CA

Xilinx, Inc. engages in the design and development of programmable logic semiconductor devices and the related software design tools. It also provides design services, customer training, field engineering, and technical support. The company was founded by Ross Freeman, Bernard Vonderschmitt, and James V. Barnett in February 1984 and is headquartered in San Jose, CA.

Waytronx, Inc. Power & Utilities | Tualatin, OR

CUI Global is a publicly traded holding company dedicated to maximizing shareholder value through the acquisition and development of innovative companies and technologies. From its GasPT2 platform targeting the energy sector, to its subsidiary CUI Inc's industry leading digital power platform targeting the networking and telecom industries, CUI Global has built a diversified portfolio of industry leading technologies that touch many markets. We pride ourselves on operating with a high level of integrity, respect, and philanthropic dedication. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, market channels of CUI Global and its subsidiaries. Our core values allow us to make a difference in the lives of our customers, community, employees, and investors. We've recently merged and streamlined resources with our subsidiary, CUI Inc., to create a unified, international brand that now positions CUI Global for further strategic expansion

Ahluwalia Contracts (India) Ltd. Engineering, Construction & Architecture | New Delhi, DE

Ahluwalia Contracts (India) Ltd. engages in the provision of construction related activities. It operates through the following segments: Contract Work, Investment Property, and Other. The Other segment comprises of real estate trading business. The company was founded by Bikramjit Ahluwalia on June 2, 1979 and is headquartered in New Delhi, India.

Competitors
Danaher Corporation Industrial Machinery & Manufacturing - Washington, DC

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following five segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products and services that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as to improve the aesthetics of the human smile. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Thermo Fisher Scientific, Inc. Industrial Machinery & Manufacturing - Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Awards & Honors
Rank #589
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Agilent Technologies, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Agilent Technologies, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Agilent Technologies, Inc..